Hydroxychloroquine monotherapy in sarcoidosis: Indications, efficacy, and side effects
Main Article Content
Keywords
Sarcoïdosis, Monotherapy, Hydroxychloroquine
Abstract
Background and aim: In sarcoidosis which is not threatening vital internal organs such as heart, central nervous system or lungs immunomodulatory treatment, such as hydroxychloroquine can be considered. Despite its common use, limited data are available regarding effectiveness and side effects as monotherapy in sarcoidosis. Recommendations on its usage are based on expert opinion as literature is scarce. Methods: This retrospective study examines real-world data about the indications, effectivity and side effects of hydroxychloroquine monotherapy in sarcoidosis patients with no damage to the vital internal organs. Successful treatment was defined as continuation after 24 weeks without step up therapy or worsening of symptoms. Results: Sixty patients were eligible for the study. Starting dose was 400mg/day, lowered to 200mg/day after 3 months in most patients. The predominant treatment indications were musculoskeletal 45 (75%) and cutaneous involvement 13 (22%). Thirty-three patients (55%) continued treatment after 24 weeks. Twenty-four patients (40%) mentioned side effects, mainly gastrointestinal, leading to treatment discontinuation in eleven patients (18%). No severe side effects were seen. Continuation after 24 weeks was significantly higher in patients with cutaneous involvement compared to other indications 85% vs 47% respectively (p =0.02). Conclusions: Treatment with hydroxychloroquine monotherapy was satisfactory in 55% of patients, especially for cutaneous involvement. However, it poses considerable non-severe side-effects.
References
2. Kahlmann V, Moor CC, Veltkamp M, Wijsenbeek MS. Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population. Chron Respir Dis [Internet]. 2021 [cited 2023 Apr 2];18:1–4. Available from: /pmc/articles/PMC8477709/
3. Thillai M, Atkins CP, Crawshaw A, et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax. 2021 Jan 1;76(1):4–20.
4. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal [Internet]. 2021 [cited 2023 Mar 4];58(21). doi:10.1183/13993003.04079-2020
5. Baughman RP, Judson MA, Wells A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases [Internet]. 2017 [cited 2022 Feb 24];34(4):280. Available from: /pmc/articles/PMC7170078/
6. Jamilloux Y, el Jammal T, Bert A, Sève P. L’hydroxychloroquine pour la sarcoïdose extra-pulmonaire non-sévère. Rev Med Interne. 2022 Jul 1;43(7):406–11.
7. Paolino A, Galloway J, Birring S, et al. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service.
8. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990 Sep 1;23(3):487–9.
9. Modi Sapna, Rosen Ted. Micropapular Cutaneous Sarcoidosis: Case Series Successfully Managed With Hydroxychloroquine Sulfate. Cutis [Internet]. 2008 Apr [cited 2023 Mar 4];81:351–4. Available from: https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/081040351.pdf
10. Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol [Internet]. 2005 Mar 1 [cited 2021 Dec 19];30(2):120–4. Available from: https://onlinelibrary-wiley-com.proxy.library.uu.nl/doi/full/10.1111/j.1365-2230.2005.01729.x
11. Ben Hassine I, Rein C, Comarmond C, et al. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. Joint Bone Spine. 2019 Nov 1;86(6):789–93.
12. DeSimone DP, Brilliant HL, Basile J, Bell NH. Granulomatous infiltration of the talus and abnormal vitamin D and calcium metabolism in a patient with sarcoidosis: Successful treatment with hydroxychloroquine. Am J Med. 1989 Dec 1;87(6):694–6.
13. Sparks JA, McSparron JI, Shah N, et al. Osseous sarcoidosis: Clinical characteristics, treatment, and outcomes—Experience from a large, academic hospital. Semin Arthritis Rheum. 2014 Dec 1;44(3):371–9.
14. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized Trial of Prolonged Chloroquine Therapy in Advanced Pulmonary Sarcoidosis. https://doi.org/101164/ajrccm16019809024 [Internet]. 2012 Dec 14 [cited 2023 Apr 13];160(1):192–7. Available from: www.atsjournals.org
15. Crouser ED, Maier LA, Baughman RP, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. https://doi.org/101164/rccm202002-0251ST [Internet]. 2020 Apr 15 [cited 2023 Apr 13];201(8):E26–51. Available from: http://www.atsjournals.org/doi/suppl/10.1164/rccm.202002-0251ST.
16. Yusuf IH, Foot B, Galloway J, et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye [Internet]. 2018 Jul 1 [cited 2022 Jan 5];32(7):1168. Available from: /pmc/articles/PMC6043500/
17. Sharma P, Bryer JS, Price S, Noe MH, Rosenbach M. A prospective comparison of cutaneous sarcoidosis disease response to immunomodulatory and immunosuppressive therapies. J Am Acad Dermatol. 2020 Jun 1;82(6):1546–8.
18. Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest [Internet]. 2013 Sep 1 [cited 2023 Apr 13];144(3):805–12. Available from: http://journal.chestnet.org/article/S0012369213605966/fulltext
19. Hydroxychloroquine bij SLE - Richtlijn - Richtlijnendatabase [Internet]. [cited 2024 May 23]. Available from: https://richtlijnendatabase.nl/richtlijn/medicamenteuze_behandeling_en_monitoren_van_systemische_lupus_erythematodes/medicamenteuze_behandeling_basis_sle/hydroxychloroquine_bij_sle.html
20. Baughman RP, Judson MA, Teirstein A, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol [Internet]. 2008 [cited 2023 Apr 13];9(3):155–61. Available from: https://pubmed.ncbi.nlm.nih.gov/18429644/
21. Saketkoo LA, Russell AM, Jensen K, et al. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel) [Internet]. 2021 Jun 1 [cited 2023 Apr 13];11(6). Available from: https://pubmed.ncbi.nlm.nih.gov/34203584/
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Marcel Veltkamp, Interstitial Lung Disease (ILD) Centre of Excellence, department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands and Division of heart and lungs, University Medical Centre, Utrecht, The Netherlands
MD,PHD
Lisette Regina Maria Raasing, Interstitial Lung Disease (ILD) Centre of Excellence, department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands
MSc
Adriane Dore Marie Vorselaars, Division of heart and lungs, University Medical Centre, Utrecht, The Netherlands
MD,PHD
How to Cite
